Professional Section Quarterly - Spring 2012 - (Page 1)

Spring 2012 IN THIS ISSUE The ADA Journals Mobile App. . . . . . . . . . 3 72nd Scientific Sessions News. . . . . . . . . 4 Diabetes is Primary CME Program. . . . . . . 8 ADA-Medtronic Diabetes Fellowship . . . . 15 Robert E. Ratner Comes Aboard as ADA Chief Scientific and Medical Officer Robert E. Ratner, MD, FACP, FACE, has joined the American Diabetes Association as its new Chief Scientific and Medical Officer. In this capacity, he oversees the Association’s research, clinical affairs, program recognition and certification, medical information, and professional education activities. Before coming to the Association, Ratner was Professor of Medicine at Georgetown University Medical School and Senior Research Scientist at the MedStar Health Research Institute, both in metropolitan Washington, D.C. While at Georgetown University, he served as the Associate Director of the General Clinical Research Center (GCRC) and Co-Director of the Participant and Clinical Interaction Resources (PCIR), sat on the University Research Committee, and cochaired the Joint Oversight Committee for Clinical Research. Ratner is already well acquainted with the operations and mission of the Association, having previously served as chair continued on page 2 Clinical News ADA and EASD Issue Statement on Hyperglycemia Management joint position statement by the American Diabetes Association and the European Association for the Study of Diabetes (EASD) on managing hyperglycemia in adults with type 2 diabetes was published concurrently in the April 19 online edition of the Association journal Diabetes Care and in EASD’s journal, Diabetologia. Titled “Management of Hyperglycemia in Type 2 A Diabetes: A Patient-Centered Approach,” the new statement is less prescriptive and algorithmic than previous recommendations on the subject. The joint statement notes that updated guidance from the two organizations was “deemed necessary because of contemporary information on the benefits/risks of glycemic control, recent evidence concerning efficacy and safety of several new drug classes, the withdrawal/restriction of othcontinued on page 2 Position Statement Writing Group American Diabetes Association Richard M. Bergenstal MD Int’l Diabetes Center, Minneapolis, MN John B. Buse MD, PhD University of North Carolina, Chapel Hill, NC Anne L. Peters MD Univ. of Southern California, Los Angeles, CA Richard Wender MD Thomas Jefferson University, Philadelphia, PA Silvio E. Inzucchi MD (co-chair) Yale University, New Haven, CT European Assoc. for the Study of Diabetes Michaela Diamant MD, PhD VU University, Amsterdam, The Netherlands Ele Ferrannini MD University of Pisa, Pisa, Italy Michael Nauck MD Diabeteszentrum, Bad Lauterberg, Germany Apostolos Tsapas MD, PhD Aristotle University, Thessaloniki, Greece David R. Matthews MD, DPhil (co-chair) Oxford University, Oxford, UK Note: A downloadable slide set accompanies the ADA/EASD position statement; this writing-group list appears on Slide 2. The set is available at professional.diabetes.org/MHSD. professional.diabetes.org http://professional.diabetes.org/MHSD http://professional.diabetes.org

Table of Contents for the Digital Edition of Professional Section Quarterly - Spring 2012

Professional Section Quarterly - Spring 2012